Results 51 to 60 of about 4,151 (165)
The American Journal on Addictions, Volume 35, Issue 1, Page 46-52, January 2026.Abstract Background Opioid use disorder (OUD) imposes a significant socioeconomic burden, highlighting the need for new interventions. Objective This study investigated whether exposure to 5‐alpha reductase inhibitors (5αRIs) is associated with a lower risk of developing OUD.
Abdelrahman G. Tawfik +5 more
wiley +1 more source
Process Factors Affecting the Preparation and Characterization of Dutasteride Nanosuspension
Dutasteride, a synthetic compound belonging to the 4-azasteroid class, functions as a selective and competitive inhibitor of both type 1 and type 2 5-alpha-reductase enzymes.
Shaimaa N. Abd-Alhammid +1 more
core +1 more source
, 2009 J Miller, TH TarterSouthern Illinois University School of Medicine, Department of Surgery, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of ...
J Miller, TH Tarter
core
, 2015 OBJECTIVES: To evaluate the correlation of clinical and urodynamic parameters with bladder vascular resistance before and after dutasteride treatment in patients with lower urinary tract symptoms associated with benign prostatic enlargement. METHODS: A
Hashizume, Kazumi +14 more
core +1 more source
Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review [PDF]
, 2017 The 5-α-reductase inhibitors finasteride and dutasteride are frequently used in the treatment of androgenetic alopecia and benign prostatichyperplasia. These drugs are effective at reducing levels of dihydrotestosterone, the primary androgen responsible ...
Gamret, A Caresse +3 more
core +1 more source
Particle size distribution of dutasteride loaded PLGA microspheres.
, 2014 Particle size distribution of dutasteride loaded PLGA microspheres.
Yanfang Yang (408813) +6 more
core +1 more source
, 2019 Background: BPH is a major cause of bothersome lower urinary tract symptoms (LUTS) and affects quality of life (QoL) which deteriorates if not taken care with the passage of time.
Tandon, Vishal R. +3 more
core +1 more source
Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride
, 2013 A recently published large, long-term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of 'cardiac failure' was noted in the dutasteride arm of the trial compared with placebo.
Loke, Y K +6 more
core +1 more source
, 2011 Background: In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, dutasteride reduced the relative risk of prostate cancer (CaP) diagnosis over a 4-year period by 22.8%, but questions remain regarding the cost–effectiveness of ...
Yair Lotan, Robert S. Svatek
core +1 more source
Dutasteride: A Review of its Use in the Management of Prostate Disorders
, 2011 Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes approved for the treatment of men with symptomatic benign prostatic hyperplasia (BPH) who have an enlarged prostate ...
E. David Crawford +2 more
core +1 more source